These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23058787)

  • 1. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
    Gallerani E; Zucchetti M; Brunelli D; Marangon E; Noberasco C; Hess D; Delmonte A; Martinelli G; Böhm S; Driessen C; De Braud F; Marsoni S; Cereda R; Sala F; D'Incalci M; Sessa C
    Eur J Cancer; 2013 Jan; 49(2):290-6. PubMed ID: 23058787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
    Vogl DT; Martin TG; Vij R; Hari P; Mikhael JR; Siegel D; Wu KL; Delforge M; Gasparetto C
    Leuk Lymphoma; 2017 Aug; 58(8):1872-1879. PubMed ID: 28140719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
    Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
    Geoerger B; Estlin EJ; Aerts I; Kearns P; Gibson B; Corradini N; Doz F; Lardelli P; Miguel BD; Soto A; Prados R; Vassal G
    Eur J Cancer; 2012 Feb; 48(3):289-96. PubMed ID: 22119199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
    Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
    J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
    Aghajanian C; Soignet S; Dizon DS; Pien CS; Adams J; Elliott PJ; Sabbatini P; Miller V; Hensley ML; Pezzulli S; Canales C; Daud A; Spriggs DR
    Clin Cancer Res; 2002 Aug; 8(8):2505-11. PubMed ID: 12171876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
    Smith DC; Kalebic T; Infante JR; Siu LL; Sullivan D; Vlahovic G; Kauh JS; Gao F; Berger AJ; Tirrell S; Gupta N; Di Bacco A; Berg D; Liu G; Lin J; Hui AM; Thompson JA
    Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.
    Delord JP; Tourani JM; Lefresne F; Pétain A; Pouget JC; Ravaud A
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):647-56. PubMed ID: 23299791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.